Review of Biologics in Children With Rheumatic Diseases

Shabina Habibi; Athimalaipet V Ramanan


Int J Clin Rheumatol. 2012;7(1):81-93. 

In This Article


Certolizumab pegol is a PEGylated Fab fragment of a humanized anti-TNF-α antibody, and golimumab is a humanized monoclonal anti-TNK-α antibody. Both of these drugs have been found to be effective for the management of adults with rheumatoid arthritis, psoriatic arthritis and Crohn's disease. Currently there are no published data from randomized controlled trials on the efficacy of these drugs in JIA. A multicenter trial of golimumab in JIA is ongoing.[101]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: